# Scleroderma, Systemic trials: 146 new since Nov 2024

Updated November 9, 2026.

146 clinical studies in Scleroderma, Systemic were first posted on ClinicalTrials.gov from November 20, 2024 to November 9, 2026; 44 have an industry sponsor and 122 are recruiting or about to. The newest, NCT07925619, was posted on November 9, 2026: Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers (Pharmosa Biopharm Inc.).

## The full list

New Scleroderma, Systemic clinical trials: 146 rows for $7.30, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 7 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/scleroderma-systemic

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 146
- Industry sponsored: 44
- Recruiting or not yet: 122
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 146, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925619 | Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers | Pharmosa Biopharm Inc. | Phase 2 | Not yet recruiting | Systemic Sclerosis | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925619) |
| November 9, 2026 | NCT07925242 | FAPI PET in Systemic Sclerosis Interstitial Lung Disease | University of California, Los Angeles | Phase 2 | Not yet recruiting | Systemic Sclerosis (SSc), Scleroderma, Interstitial Lung Disease With Systemic Sclerosis | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925242) |
| November 9, 2026 | NCT07924124 | Small Airway Dysfunction in Rheumatoid Arthritis and Systemic Sclerosis | Assistance Publique - Hôpitaux de Paris | Not applicable | Not yet recruiting | Rhumatoid Arthisis, Systemic Sclerosis (SSc) | 184 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924124) |
| November 4, 2026 | NCT07916324 | Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma | Stanford University | Phase 2 | Not yet recruiting | Scleroderma, Sclerodactyly, Systemic Sclerosis | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916324) |
| October 30, 2026 | NCT07906145 | A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA), Primary Sjögren's Syndrome (pSS), Systemic Sclerosis (SSc) | 76 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906145) |
| October 22, 2026 | NCT07888842 | A Clinical Study on Systemic Sclerosis and the Validation of French-language Questionnaires Assessing Disability, Quality of Life, and... | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Scleroderma | 200 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888842) |
| October 14, 2026 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic... | 60 | Belgium, France, Germany, Netherlands, Poland, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873931) |
| October 5, 2026 | NCT07858838 | Using AI-Assisted Cameras to Track Hand Exercises in Scleroderma Patients | Istanbul University - Cerrahpasa | Not applicable | Not yet recruiting | Systemic Scleroderma | 40 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858838) |
| October 2, 2026 | NCT07854483 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory... | AbelZeta Inc. | Phase 1 | Not yet recruiting | Systemic Sclerosis (SSc), Systemic Sclerosis, Systemic Sclerosis (Scleroderma), Systemic Sclerosis - 2013 ACR/EULAR... | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854483) |
| September 25, 2026 | NCT07842523 | Obinutuzumab in Systemic Sclerosis | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Systemic Sclerosis in Adults | 120 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842523) |
| September 25, 2026 | NCT07842133 | The Effect of Progressive Muscle Relaxation Exercises on Fatigue, Dyspnea, and Respiratory Function in Patients With Systemic Sclerosis | University of Gaziantep | Not applicable | Recruiting | Systemic Sclerosis (SSc) | 50 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842133) |
| September 25, 2026 | NCT07840430 | Home-based Exercise for Improving Health-related Quality of Life in Systemic Sclerosis | University of Aarhus | Not applicable | Not yet recruiting | Systemic Sclerosis (SSc) | 270 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840430) |
| September 24, 2026 | NCT07839221 | Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic Sclerosis | Assiut University | Observational | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Interstitial Lung Disease (ILD) | 110 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839221) |
| September 24, 2026 | NCT07837986 | Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies | Hospices Civils de Lyon | Not applicable | Not yet recruiting | Systememic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathies, Connective Tissue Diseases, Type 1... | 120 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837986) |
| September 23, 2026 | NCT07836361 | Clinical Cohort Study of Systemic Sclerosis | Peking University Third Hospital | Observational | Recruiting | Sclerosis, Systemic | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836361) |
| September 18, 2026 | NCT07827742 | Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Systemic Sclerosis in Adults | 120 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827742) |
| September 15, 2026 | NCT07821398 | Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis | Bastiaan Driehuys | Phase 2 | Not yet recruiting | Interstitial Lung Disease, Pulmonary Hypertension, Systemic Sclerosis | 51 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821398) |
| September 8, 2026 | NCT07806045 | Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement | Qiubai Li | Early phase 1 | Not yet recruiting | IgG4 Related Disease, Systemic Sclerosis (SSc) | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806045) |
| September 2, 2026 | NCT07800871 | FT839 in Autoimmune Diseases | Fate Therapeutics | Phase 1/2 | Recruiting | ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus... | 446 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800871) |
| August 24, 2026 | NCT07782450 | A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases | Pfizer | Phase 1/2 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, Systemic Sclerosis | 54 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782450) |
| August 21, 2026 | NCT07778446 | A Study to Test CRT-402 in Refractory Autoimmune Disease | Myeloid Therapeutics | Phase 1/2 | Recruiting | Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma, Myositis | 34 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778446) |
| August 12, 2026 | NCT07759557 | Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary Raynaud's Phenomenon | Khon Kaen University | Phase 3 | Not yet recruiting | Systemic Sclerosis (SSc), Raynaud Disease Secondary to Scleroderma | 72 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759557) |
| August 5, 2026 | NCT07748000 | A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks | Liquidia Technologies, Inc. | Phase 2 | Not yet recruiting | Raynaud's Phenomenon Secondary to Systemic Sclerosis | 75 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748000) |
| August 4, 2026 | NCT07745725 | A Phase II Study of TollB-001 Tablets in Systemic Sclerosis | Toll Biotech Co. Ltd. (Beijing) | Phase 2 | Not yet recruiting | Systemic Sclerosis (SSc) | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745725) |
| July 30, 2026 | NCT07737470 | Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Pericarditis, Tako-TSUBO Cardiomyopathy, Myocarditis, Inflammatory Cardiomyopathies, Lupus, Systemic Sclerosis... | 300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737470) |
| July 29, 2026 | NCT07734012 | Mycophenolate After Stem Cell Transplant for Systemic Sclerosis | Ottawa Hospital Research Institute | Phase 2 | Not yet recruiting | Systemic Sclerosis (SSc) | 6 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734012) |
| July 28, 2026 | NCT07732309 | A Study of ATG-201 in Adult Participants With Autoimmune Diseases | Antengene Biologics Limited | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases | 149 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732309) |
| July 28, 2026 | NCT07729995 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease | Luminary Therapeutics | Phase 1 | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc) | 94 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729995) |
| July 23, 2026 | NCT07723872 | Finger Versus Earlobe Pulse Oximetry During the 6-Minute Walk Test in Interstitial Lung Disease | Hospital de Granollers | Observational | Recruiting | Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis, Connective Tissue... | 100 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723872) |
| July 21, 2026 | NCT07717060 | Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Not applicable | Not yet recruiting | Systemic Sclerosis, Pulmonary Arterial Hypertension, Digital Ulcers, Vascular Complications | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717060) |
| July 13, 2026 | NCT07697274 | Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial | Medical University of South Carolina | Early phase 1 | Not yet recruiting | Systemic Sclerosis, Sclerodactyly | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697274) |
| June 30, 2026 | NCT07676266 | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | The Affiliated Hospital of Qingdao University | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus... | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676266) |
| June 22, 2026 | NCT07661836 | Personalized Online Occupational Therapy Intervention for Adults With Scleroderma | Universidad de Zaragoza | Not applicable | Completed | Scleroderma, Scleroderma (Limited and Diffuse), Systemic Sclerosis (SSc) | 24 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661836) |
| June 16, 2026 | NCT07650565 | Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs) | University Hospital, Montpellier | Not applicable | Recruiting | Systemic Sclerosis (SSc) | 16 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07650565) |
| June 16, 2026 | NCT07649265 | A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease | 63 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649265) |
| June 11, 2026 | NCT07642297 | TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP) | Fondazione Policlinico Universitario Campus Bio-Medico | Observational | Not yet recruiting | Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis, Skin Fibrosis | 20 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642297) |
| June 11, 2026 | NCT07641634 | A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. | Prolium Bioscience, Inc | Phase 1/2 | Recruiting | Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma | 44 | Australia, China, Mexico, South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641634) |
| May 19, 2026 | NCT07596680 | CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases | Nanjing Bioheng Biotech Co., Ltd. | Early phase 1 | Not yet recruiting | SLE - Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies... | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596680) |
| May 14, 2026 | NCT07586267 | CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease | The Children's Hospital of Zhejiang University School of Medicine | Early phase 1 | Recruiting | Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy... | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586267) |
| April 30, 2026 | NCT07558850 | Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases | The First Affiliated Hospital with Nanjing Medical University | Not applicable | Recruiting | Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus, Systemic Sclerosis | 72 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558850) |
| April 22, 2026 | NCT07544225 | Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic... | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren's Disease With Dry Eyes, Systemic Sclerosis... | 6 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544225) |
| April 22, 2026 | NCT07543679 | Objective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis | Centre Hospitalier Universitaire de Saint Etienne | Not applicable | Recruiting | D013493 | 100 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543679) |
| April 21, 2026 | NCT07542067 | Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With... | Fundación Neumologica Colombiana | Phase 1/2 | Completed | Systemic Sclerosis Pulmonary, Pulmonary Hypertension, Pulmonary Fibrosis | 1 | Colombia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07542067) |
| April 17, 2026 | NCT07535931 | Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis | Shenzhen Huishan Biotechnology Co., Ltd. | Phase 1/2 | Not yet recruiting | Systemic Sclerosis (SSc) | 21 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07535931) |
| April 14, 2026 | NCT07527936 | A Study of BEN301 Injection in theTreatment of Autoimmune Diseases | RenJi Hospital | Early phase 1 | Suspended | Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Sjogren's Syndrome (SS), Idiopathic Inflammatory Myopathies(IIM) | 24 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527936) |
| April 13, 2026 | NCT07526350 | MTS109 in Patients With Refractory Autoimmune Diseases | Shanghai Changzheng Hospital | Early phase 1 | Recruiting | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc), ANCA-Associated Vasculitis... | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07526350) |
| April 13, 2026 | NCT07523282 | Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases | Shenzhen MagicRNA Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Autoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523282) |
| April 7, 2026 | NCT07515638 | Immun4Cure Cohort of Autoimmune Diseases | University Hospital, Montpellier | Observational | Recruiting | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Healthy Adult Volunteers | 500 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515638) |
| April 2, 2026 | NCT07507201 | Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease | The Children's Hospital of Zhejiang University School of Medicine | Early phase 1 | Recruiting | Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy... | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07507201) |
| March 30, 2026 | NCT07502105 | Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis | Tongji Hospital | Not applicable | Not yet recruiting | Systemic Scleroderma | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502105) |
| March 27, 2026 | NCT07497087 | A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis | Boehringer Ingelheim | Phase 3 | Recruiting | Systemic Sclerosis | 448 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497087) |
| March 25, 2026 | NCT07493395 | Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy | University Hospital, Montpellier | Phase 2 | Recruiting | Scleroderma, Systemic | 6 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493395) |
| March 16, 2026 | NCT07473154 | Controlling Hyperactive Immunity With Long-lived Lymphocytes | Quell Therapeutics Limited | Phase 1/2 | Recruiting | Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic... | 16 | Germany, Spain, United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473154) |
| March 16, 2026 | NCT07472166 | Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 4 | Completed | Scleroderma, Systemic | 34 | Bangladesh | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472166) |
| March 13, 2026 | NCT07469865 | Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST) | University Hospital, Ghent | Not applicable | Completed | Dry Eye Disease | 46 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07469865) |
| February 17, 2026 | NCT07413341 | A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases | Therorna | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA... | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413341) |
| February 11, 2026 | NCT07403188 | A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 | Kyverna Therapeutics | Observational | Recruiting | Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis... | 70 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07403188) |
| February 11, 2026 | NCT07402863 | Self-Guided Resilience-Building Energy Management to Enhance Well-being (RENEW) Intervention for People With Systemic Sclerosis (SSc) | University of Michigan | Not applicable | Completed | Systemic Sclerosis | 43 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07402863) |
| February 11, 2026 | NCT07402226 | Systemic Sclerosis DIet for GastrointESTinal Symptoms | University of Michigan | Not applicable | Recruiting | Systemic Sclerosis (SSc) | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07402226) |
| February 6, 2026 | NCT07393217 | Correlation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic... | Sohag University | Observational | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc) | 111 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07393217) |
| January 22, 2026 | NCT07361094 | Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases | Beijing Boren Hospital | Phase 1 | Withdrawn | Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, Relapsed/Refractory... | 0 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07361094) |
| January 22, 2026 | NCT07360808 | Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis | Cytori Therapeutics | Not applicable | Recruiting | Systemic Sclerosis (SSc), Hand Dysfunction | 48 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07360808) |
| January 15, 2026 | NCT07345052 | Western Sweden Systemic Sclerosis Project | Sahlgrenska University Hospital | Observational | Recruiting | Scleroderma, Systemic, Fibrosis; Skin, Fibrosis Lung, Interstitial Lung Disease Due to Systemic Disease | 150 | Sweden | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07345052) |
| January 15, 2026 | NCT07343115 | Familial Systemic Scleroderma | University Hospital, Strasbourg, France | Observational | Recruiting | Systemic Scleroderma | 20 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07343115) |
| January 14, 2026 | NCT07339540 | the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases | Tongji Hospital | Early phase 1 | Active not recruiting | Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases, Recurrent or... | 45 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339540) |
| January 13, 2026 | NCT07335562 | A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care... | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 3 | Not yet recruiting | Systemic Sclerosis | 92 | Belgium, Canada, France, Germany, Italy, Japan, Spain, Switzerland, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07335562) |
| January 8, 2026 | NCT07326033 | Efficacy and Safety of Allogenic Cultured Adipose-derived Mesenchymal Stromal Cell Injections on MoUth Fibrosis and Handicap in Patients... | University Hospital, Toulouse | Phase 2 | Not yet recruiting | Systemic Scleroderma | 50 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326033) |
| December 26, 2025 | NCT07305116 | CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 | Recruiting | Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy... | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07305116) |
| December 24, 2025 | NCT07301164 | Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases | Peking University Third Hospital | Early phase 1 | Recruiting | System Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myositis, Antiphospholipid Syndrome, ANCA Associated... | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301164) |
| December 22, 2025 | NCT07295847 | A Study of AZD0120 in Autoimmune Diseases | AstraZeneca | Phase 1/2 | Recruiting | Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis | 27 | Australia, Germany, Spain, Sweden, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07295847) |
| December 18, 2025 | NCT07292961 | Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma | Hacettepe University | Not applicable | Recruiting | Scleroderma, Scleroderma, Localized, Scleroderma Systemic, Scleroderma (Limited and Diffuse), Systemic Sclerosis (SSc)... | 48 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292961) |
| December 16, 2025 | NCT07284797 | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases | Xencor, Inc. | Phase 1 | Recruiting | Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease | 60 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284797) |
| December 11, 2025 | NCT07277491 | Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity | Cairo University | Observational | Completed | Spondyloarthritis (SpA), Psoriatic Arthritis (PsA), Systemic Lupus Erythematous (SLE), Systemic Sclerosis (SSc)... | 460 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277491) |
| November 26, 2025 | NCT07251179 | Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies | University Hospital, Strasbourg, France | Observational | Recruiting | Systemic Lupus Erythematosus, Systemic Scleroderma, ANCA-associated Vasculitis, Antiphospholipid Syndrome, Primary... | 200 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07251179) |
| November 25, 2025 | NCT07249060 | Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients | Hospital Universitario Araba | Observational | Recruiting | Immune-Related Adverse Events, Lupus Erythematosus, Systemic, Sjogren Syndrome, Systemic Sclerosis (SSc), Inflammatory... | 300 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249060) |
| November 24, 2025 | NCT07246096 | Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory... | Changhai Hospital | Early phase 1 | Recruiting | Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis, Primary Sjögren Syndrome, Rheumatoid Arthritis... | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246096) |
| November 24, 2025 | NCT07245238 | Topical Cannabidiol Lotion for Pruritus Relief in Scleroderma | Khon Kaen University | Phase 3 | Recruiting | Mediciine, Systemic Sclerosis (SSc), Intervention Study | 36 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07245238) |
| November 19, 2025 | NCT07236970 | Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With... | Alejandro Cruz Utrilla | Observational | Recruiting | Pulmonary Hypertension, Systemic Sclerosis (SSc), Systemic Sclerosis-Associated PAH | 350 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236970) |
| November 19, 2025 | NCT07236801 | Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS), Inflammatory Myopathy, Anti-Neutrophil... | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236801) |
| November 14, 2025 | NCT07228429 | Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images | Yale University | Observational | Recruiting | Systemic Sclerosis (SSc), Calcinosis Cutis | 56 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228429) |
| October 8, 2025 | NCT07212959 | As Part of a Pilot Study, Visualization of Inflammatory Activity in Systemic Sclerosis Using CXCR4 PET/CT | Wuerzburg University Hospital | Not applicable | Completed | Systemic Sclerosis (SSc) | 12 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07212959) |
| October 8, 2025 | NCT07212322 | A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases | Institute of Hematology & Blood Diseases Hospital, China | Not applicable | Not yet recruiting | Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated... | 24 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07212322) |
| October 7, 2025 | NCT07209644 | Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis | Assiut University | Observational | Not yet recruiting | Systemic Sclerosis | 70 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209644) |
| September 23, 2025 | NCT07188285 | Mass Spectrometry-based Immune Profiling in Autoimmune Diseases | Peking University People's Hospital | Observational | Enrolling by invitation | Systemic Lupus Erthematosus, Sjogren's Syndrome, Inflammatory Myopathies, Systemic Sclerosis (SSc), Vasculitis... | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07188285) |
| September 19, 2025 | NCT07184450 | Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary... | 11 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07184450) |
| September 19, 2025 | NCT07183072 | Patients Diagnosed With Scleroderma: Physical Performance and Functionality | Hacettepe University | Observational | Recruiting | Systemic Sclerosis (SSc), Scleroderma, Scleroderma (Limited and Diffuse), Scleroderma, Localized, Functionality | 50 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07183072) |
| September 19, 2025 | NCT07182981 | Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance | Hacettepe University | Observational | Recruiting | Systemic Sclerosis (SSc), Scleroderma, Scleroderma (Limited and Diffuse), Scleroderma, Localized, Swallowing | 50 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07182981) |
| September 19, 2025 | NCT07182968 | Cultural Adaptation, Validity, and Reliability of the Turkish Version of The PASTUL Questionnaire | Hacettepe University | Observational | Recruiting | Systemic Sclerosis (SSc), Systemic Sclerosis (Scleroderma), Scleroderma (Limited and Diffuse), Patient Perspective | 50 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07182968) |
| September 16, 2025 | NCT07175246 | Exploring the Patterns of Sleep Disordered Breathing in Systemic Sclerosis Patients | Assiut University | Observational | Not yet recruiting | Systemic Sclerosis, Sleep-Disordered Breathing | 30 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175246) |
| September 11, 2025 | NCT07167537 | A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases | Beijing GoBroad Hospital | Phase 1 | Recruiting | Systemic Sclerosis (SSc), Primary Sjogren's Syndrome | 44 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07167537) |
| September 8, 2025 | NCT07159009 | A Study of GB261 in Systemic Sclerosis | Ruijin Hospital | Early phase 1 | Not yet recruiting | Systemic Sclerosis (SSc) | 10 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07159009) |
| September 8, 2025 | NCT07158996 | A Study of Cizutamig in Systemic Sclerosis | Ruijin Hospital | Early phase 1 | Not yet recruiting | Systemic Sclerosis (SSc) | 10 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07158996) |
| September 4, 2025 | NCT07155369 | UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases | The Affiliated Hospital of Xuzhou Medical University | Not applicable | Active not recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07155369) |
| September 2, 2025 | NCT07150000 | Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy | University of Bonn | Observational | Recruiting | Rheumatic Diseases, Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA), Psoriatic Arthritis (PsA), Axial... | 120 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07150000) |
| August 13, 2025 | NCT07121777 | Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases | Anhui Provincial Hospital | Not applicable | Recruiting | Autoimmune Diseases | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07121777) |
| August 11, 2025 | NCT07115745 | A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 | Recruiting | Refractory Autoimmune Diseases | 125 | Australia, Brazil, Czechia, France, Germany, Israel, Poland, Romania, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115745) |
| August 8, 2025 | NCT07112183 | Open Label Treprostinil Raynaud's Study | Brigham and Women's Hospital | Phase 4 | Recruiting | Raynaud's Disease, Raynaud Phenomena, Raynauds | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07112183) |
| August 5, 2025 | NCT07104721 | A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy... | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104721) |
| July 29, 2025 | NCT07090226 | Diffuse Cutaneous Scleroderma (DSSc) SFDI Study | Boston University | Not applicable | Recruiting | Systemic Scleroderma, Diffuse Cutaneous Scleroderma | 65 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07090226) |
| July 28, 2025 | NCT07087912 | Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases | University of Sao Paulo General Hospital | Phase 4 | Recruiting | Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic... | 477 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07087912) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Assistance Publique - Hôpitaux de Paris | 7 | November 9, 2026 |
| Beijing GoBroad Hospital | 5 | September 11, 2025 |
| Assiut University | 4 | September 24, 2026 |
| Peking University Third Hospital | 4 | September 23, 2026 |
| The Children's Hospital of Zhejiang University School of Medicine | 4 | May 14, 2026 |
| Hacettepe University | 4 | December 18, 2025 |
| Khon Kaen University | 3 | August 12, 2026 |
| University Hospital, Montpellier | 3 | June 16, 2026 |
| University of Michigan | 3 | February 11, 2026 |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 3 | November 19, 2025 |
| Istanbul University - Cerrahpasa | 2 | October 5, 2026 |
| Nanjing Bioheng Biotech Co., Ltd. | 2 | May 19, 2026 |
| Tongji Hospital | 2 | March 30, 2026 |
| University Hospital, Strasbourg, France | 2 | January 15, 2026 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2 | January 13, 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 | October 8, 2025 |
| Peking University People's Hospital | 2 | September 23, 2025 |
| Ruijin Hospital | 2 | September 8, 2025 |
| Anhui Provincial Hospital | 2 | August 13, 2025 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2 | May 21, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 30 | October 30, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 29 | November 9, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 29 | October 22, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 19 | September 8, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 17 | November 9, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 15 | September 2, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 4 | August 12, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 3 | March 16, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 47 | September 23, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 27 | November 9, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 20 | November 9, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 12 | July 23, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 10 | October 14, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 8 | August 21, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 7 | October 5, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 6 | July 29, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 6 | March 27, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 5 | October 14, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 5 | October 14, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 4 | June 11, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 4 | March 27, 2026 |
| [Romania](https://specstream.ai/data/clinical-trials/country/romania) | 4 | March 27, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 4 | March 27, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 4 | February 6, 2026 |
| [Mexico](https://specstream.ai/data/clinical-trials/country/mexico) | 3 | June 11, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 3 | June 11, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 3 | March 27, 2026 |
| [Norway](https://specstream.ai/data/clinical-trials/country/norway) | 3 | March 27, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 3 | March 27, 2026 |
| [Thailand](https://specstream.ai/data/clinical-trials/country/thailand) | 3 | March 27, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 2 | October 14, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 2 | September 25, 2026 |
| [Colombia](https://specstream.ai/data/clinical-trials/country/colombia) | 2 | April 21, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).